A new population survey published in the Journal of Sexual Medicine has found that in spite of low sales after flibanserin’s approval in the U.S., there is in fact, a demand among women for sexuality-boosting medication. The researchers’ results suggest that the marketing of the drug is the problem with sales, not a lack of demand. According to the results of this new research two out of three women are “rather willing” or “definitely willing” to take sexuality-boosting medication. Conducted by researchers from the University of Zurich in Switzerland and Auckland University of Technology in New Zealand, the cross-sectional online ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.